Immune checkpoint blockade in CNS tumors [electronic resource] / David A. Reardon.

By: Reardon, David A [spk]Material type: FilmFilmSeries: Henry Stewart talksBiomedical & life sciences collection. Immunotherapy of cancer: Publisher: London : Henry Stewart Talks, 2016Description: 1 online resource (1 streaming video file (48 min.) : color, sound)Subject(s): Antineoplastic agents | Brain -- Cancer -- Chemotherapy | Brain -- Cancer -- Immunological aspects | Brain -- Cancer -- Treatment | Central nervous system -- Cancer | Glioblastoma Multiforme | Immunotherapy | Antineoplastic Agents -- therapeutic use | Brain Neoplasms -- drug therapy | Brain Neoplasms -- immunology | Central Nervous System Neoplasms -- immunology | Glioblastoma -- immunology | Glioblastoma -- therapy | Immunologic Factors -- pharmacology | Immunologic Memory | Immunosuppressive Agents | ImmunotherapyOnline resources: Click here to access online | Series
Contents:
Contents: Immunotherapy in oncology -- CNS immunoprivilege -- Glioblastoma (GBM): complexity/redundancy/heterogeneity -- "Established" and "Advanced" GBM models -- Tumor-specific immune response in GBM -- Importance of heterogeneity -- Overcoming challenges for durable GBM benefit -- Neoantigen mutations -- Checkpoint blockade & immunologic memory -- GBM vaccines -- Personalized neoantigen vaccine ("NeoVax") -- Immunotherapy response assessment in neuro-oncology (iRANO) -- Clinical trials in neuro-oncology -- Immunosuppressive mechanisms in GBM -- Combination anti-tumor immunotherapy.
Tags from this library: No tags from this library for this title. Log in to add tags.
    Average rating: 0.0 (0 votes)
No physical items for this record

Animated audio-visual presentation with synchronized narration.

Title from title frames.

Contents: Immunotherapy in oncology -- CNS immunoprivilege -- Glioblastoma (GBM): complexity/redundancy/heterogeneity -- "Established" and "Advanced" GBM models -- Tumor-specific immune response in GBM -- Importance of heterogeneity -- Overcoming challenges for durable GBM benefit -- Neoantigen mutations -- Checkpoint blockade & immunologic memory -- GBM vaccines -- Personalized neoantigen vaccine ("NeoVax") -- Immunotherapy response assessment in neuro-oncology (iRANO) -- Clinical trials in neuro-oncology -- Immunosuppressive mechanisms in GBM -- Combination anti-tumor immunotherapy.

Access restricted to subscribers.

Mode of access: World Wide Web.

Technical University of Mombasa
Tom Mboya Street, Tudor 90420-80100 , Mombasa Kenya
Tel: (254)41-2492222/3 Fax: 2490571